| Code | CSB-RA008543MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CD16A-AFM13, targeting FCGR3A (Fc gamma receptor IIIA), also known as CD16A. FCGR3A is a low-affinity receptor for the Fc region of immunoglobulin G, predominantly expressed on natural killer (NK) cells, macrophages, and certain T cell subsets. This receptor plays a critical role in antibody-dependent cellular cytotoxicity (ADCC), a key mechanism by which immune cells recognize and destroy antibody-coated target cells. FCGR3A is particularly important in antitumor immunity and immune surveillance, with genetic polymorphisms in this receptor influencing therapeutic antibody efficacy in cancer treatment and susceptibility to autoimmune disorders.
The reference antibody CD16A-AFM13 represents an important tool for investigating FCGR3A-mediated immune responses and NK cell biology. This biosimilar antibody serves as a valuable reagent for researchers studying innate immunity, cancer immunotherapy mechanisms, ADCC pathways, and the functional consequences of FCGR3A polymorphisms. It enables investigation of NK cell activation, immune cell interactions, and therapeutic antibody mechanisms in various experimental contexts.
There are currently no reviews for this product.